153 results
Page 4 of 8
8-K
EX-99.1
2anpfhe9dlsyw
14 Dec 21
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
7:02am
8-K
EX-3.2
pluftybb mxcasdlkek
8 Nov 21
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s
7:32am
424B5
0991 6v62hnne
11 Aug 21
Prospectus supplement for primary offering
6:56am
8-K
EX-10.1
79nx5i9al8dui6
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-4.2
y7ss8i
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-4.1
2m8tohw0u va
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
424B3
3rfx5hzlvyez2stm
30 Apr 21
Prospectus supplement
5:01pm
8-K
EX-99.1
4r8kr 8ide
1 Feb 21
Departure of Directors or Certain Officers
6:55am
8-K
EX-4.1
ubh23lafh1sql959t7o
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-10.1
dd6zneime dqk
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-10.2
ojn059ta2jb30dnciu
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am